Handgrip strength in patients with type 2 diabetes correlates with diabetic polyneuropathy. A single-center, retrospective observational study in Japanese patients
Endocrine Journal,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 1, 2025
Nerve
conduction
studies
(NCS)
are
the
standard
method
for
diagnosing
diabetic
polyneuropathy.
Because
a
clear
association
between
handgrip
strength
and
neuropathy
can
serve
as
screening
tool,
present
study
evaluated
NCS
diabetes-related
complications.
A
total
of
436
patients
with
type
2
diabetes
(T2D)
who
were
admitted
to
our
hospital
April
1,
2018
March
31,
2023,
using
Baba's
classification
(BDC)
included.
The
participants
grouped
by
sex
grip
tertile
assess
correlations
prevalence
microvascular
complications
in
high-handgrip
group
(HG),
middle-handgrip
(MG),
low-handgrip
(LG).
percentage
BDC-0
was
65%
HG,
54%
MG,
36%
LG.
Furthermore,
none
HG
had
BDC-3/4,
whereas
4%
MG
15%
LG
BDC-3/4.
morbidity
progression
seen
order
LG,
(p
<
0.001).
Patients
T2D
advanced
decreased
strength.
Early
evaluation
BDC
other
should
be
considered
if
is
evident.
Язык: Английский
Real world evidence of insulin and biosimilar insulin therapy—Opportunities to improve adherence, outcomes and cost‐effectiveness
Diabetes Obesity and Metabolism,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 15, 2025
Abstract
Insulin
has
been
discovered
for
more
than
a
century;
however,
its
benefits
to
people
with
diabetes
are
yet
be
fully
realized
due
barriers
related
access,
quality
of
care
and
costs.
therapy
remains
the
cornerstone
management.
The
multicausality
subtypes
calls
comprehensive
phenotyping
use
biomarkers
ensure
timely
insulin
achieve
early
glycaemic
control
long‐term
benefits.
Biosimilar
insulins
biologic
products
that
closely
resemble
originator
without
significant
differences
in
safety
or
efficacy.
lower
investment
costs
needed
research
development
make
biosimilar
affordable
improve
access.
While
efficacy
is
proven
controlled
settings,
real
world
evidence
(RWE)
from
data
(RWD)
plays
crucial
role
assessing
safety,
efficacy,
cost‐effectiveness,
adherence
impacts
different
products,
including
biosimilars,
on
clinical
outcomes.
In
this
narrative
review,
we
summarized
trends
patterns
utilization
practice
across
regions.
We
reviewed
RWE
cost‐effectiveness
insulin,
as
well
therapeutic
inertia
non‐adherence
therapy.
also
highlighted
enablers
persistence,
along
potential
solutions
promote
technologies
optimizing
diabetes.
During
our
extensive
literature
identified
gaps
usage
practice.
advocate
implementing
register
designed
fit‐for‐purpose,
managed
by
trained
doctor–nurse
team
system
support,
generate
RWE.
By
setting
up
registers
structured
collection,
can
high
integrative
analysis
electronic
health
records
(EHR)
claims
evaluate
other
programmes
outcomes,
life
healthcare
inform
policies.
Plain
Language
Summary
Diabetes
affects
approximately
10.5%
global
population
vital
treatment
was
century
ago,
although
care,
Real‐world
real‐world
to,
publication,
authors
provided
detailed
review
major
gaps.
explained
methodology,
utility,
limitations
generating
based
sources
such
registers,
effectiveness
safety.
proposed
implementation
purpose‐built
support.
These
high‐quality
integrated
evaluation
interventions,
life,
policy.
Based
these
premises
available
data,
products.
They
like
non‐adherence,
discussed
programs
Язык: Английский
Use of SGLT2 Inhibitors Versus DPP-4 Inhibitors and Age-Related Macular Degeneration in Patients WithType 2 Diabetes: A Multinational Cohort Study
Investigative Ophthalmology & Visual Science,
Год журнала:
2025,
Номер
66(4), С. 58 - 58
Опубликована: Апрель 21, 2025
To
compare
the
impact
of
sodium-glucose
cotransporter
2
(SGLT2)
and
dipeptidyl
peptidase
4
(DPP-4)
inhibitors
on
age-related
macular
degeneration
(AMD)
risk
among
patients
with
type
diabetes
mellitus
(T2DM).
This
multinational,
retrospective
cohort
study
used
electronic
medical
records
from
healthcare
institutions
across
21
countries.
Adults
50
years
or
older
T2DM
who
had
a
prior
prescription
metformin
initiated
SGLT2
DPP-4
2013
to
2023
were
included.
The
inhibitor
groups
propensity
score
matched
in
1:1
ratio
balance
baseline
characteristics
followed
for
up
5
observe
occurrence
AMD.
Statistical
analysis
was
performed
using
Cox
proportional
hazards
model
Kaplan-Meier
analysis.
Our
final
included
20,966
prescribed
inhibitors.
Compared
group,
group
associated
significantly
lower
risks
AMD
(hazard
[HR],
0.71;
95%
confidence
interval
[CI],
0.58-0.85)
dry
(HR,
0.61;
CI,
0.46-0.80)
but
not
wet
0.74;
0.48-1.16).
compared
linked
reduced
White
population,
empagliflozin
dapagliflozin,
individuals
glycated
hemoglobin
<
8.5%,
estimated
glomerular
filtration
rate
≥
60
mL/min/1.73
m2,
hypertension,
dyslipidemia,
regardless
body
mass
index
level.
In
T2DM,
those
may
experience
Язык: Английский
Utilization and cost of non‐insulin glucose‐lowering drugs in Australia from 2013 to 2023
Diabetes Obesity and Metabolism,
Год журнала:
2024,
Номер
26(11), С. 4924 - 4932
Опубликована: Сен. 2, 2024
To
investigate
the
utilization
and
costs
of
non-insulin
glucose-lowering
drugs
(GLDs)
in
Australia
from
2013
to
2023.
Язык: Английский
Glycemic control and prescription profiles in internal medicine inpatients: The role of frailty
European Journal of Internal Medicine,
Год журнала:
2023,
Номер
121, С. 103 - 108
Опубликована: Окт. 21, 2023
Язык: Английский
Use of, time to, and type of first add‐on anti‐hyperglycaemic therapy to metformin in Australia, 2018–2022
British Journal of Clinical Pharmacology,
Год журнала:
2024,
Номер
unknown
Опубликована: Сен. 3, 2024
Abstract
Aims
The
aim
of
this
study
was
to
examine
contemporary
trends
in
the
use
of,
time
to,
and
type
first
add‐on
anti‐hyperglycaemic
therapy
metformin
Australia.
Methods
We
used
dispensing
records
a
10%
random
sample
Pharmaceutical
Benefits
Scheme
(PBS)
eligible
people.
included
people
aged
40
years
older
initiating
from
1
January
2018
31
December
2020.
Our
primary
outcome
medicine
within
2
initiation.
analysed
therapy.
All
analyses
were
stratified
by
initiation
year.
Results
Overall,
38
747
initiated
between
Approximately
one‐third
(
n
=
12
946)
received
with
proportion
increasing
slightly
year
(32.3%
34.8%
2020).
Amongst
following
initiation,
sodium‐glucose
cotransporter
inhibitor
(SGLT2i)
increased
28.8%
(2018)
35.0%
(2020),
glucagon‐like
peptide‐1
receptor
agonists
(GLP‐1
RA)
3.0%
9.6%,
respectively.
Dipeptidyl
peptidase‐4
inhibitors
sulfonylureas
as
decreased
insulin
remained
stable.
One‐third
on
same
day
initiated,
i.e.
initial
combination
Conclusions
2020,
there
an
SGLT2i
GLP‐1
RA
being
However,
overall
prevalence
low.
Advocacy
promote
cardiorenal
beneficial
medicines
is
critical
reduce
diabetes
morbidity
mortality.
Язык: Английский
The impact of sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists on insulin utilisation and costs in Australia: a national retrospective observational cross-sectional study
The Lancet Regional Health - Western Pacific,
Год журнала:
2024,
Номер
52, С. 101207 - 101207
Опубликована: Сен. 24, 2024
Язык: Английский
Noninsulin antidiabetic prescription patterns in Colombia: a cross-sectional study
Therapeutic Advances in Endocrinology and Metabolism,
Год журнала:
2024,
Номер
15
Опубликована: Янв. 1, 2024
Background:
The
prevalence
of
type
2
diabetes
mellitus
(T2DM)
continues
to
increase;
the
clinical
practice
guidelines
continue
modify
recommendations
for
its
treatment.
Objective:
aim
was
determine
prescription
patterns
noninsulin
antidiabetics
in
a
group
patients
from
Colombia.
Design:
Cross-sectional
study.
Methods:
use
antidiabetic
drugs
based
on
population
database
under
treatment
2022.
Comorbidities
were
identified,
including
total
numbers,
proportions,
and
defined
daily
doses
each
agent
per
1000
inhabitants/day
(DHD).
Results:
A
155,381
with
T2DM
mean
age
67.1
±
12.0
years.
most
widely
used
according
DHD
metformin
(9.46
DHD),
empagliflozin
(5.3),
sitagliptin
(2.8),
linagliptin
(2.4),
dapagliflozin
(2.3),
mainly
combination
therapy
(55.5%),
often
two
(31.2%
patients)
or
three
(22.4%
patients).
frequent
cardiovascular
comorbidities
hypertension
(67.6%),
chronic
kidney
disease
(6.3%),
coronary
ischemic
heart
(2.5%),
treated
angiotensin
receptor
antagonists,
followed
by
diuretics,
calcium
β-blockers.
Conclusion:
This
has
been
alone
other
drugs,
but
despite
changes
recent
years,
significant
number
concomitant
conditions
are
not
receiving
appropriate
agents.
Sodium-glucose
cotransporter
glucagon-like
peptide-1
agonists
may
offer
additional
benefits
reduced
risk.
Язык: Английский